FinVector
FinVector is a leading biopharmaceutical company specializing in the manufacturing of viral-based gene therapy products. With over 30 years of experience, the company is committed to improving lives through innovative gene therapy solutions, including treatments for cancer such as bladder cancer. Located in Kuopio, Finland, FinVector operates state-of-the-art facilities and collaborates closely with academic and industry partners to advance healthcare innovation. The company emphasizes a culture of science, collaboration, and delivering hope to patients worldwide.
Industries
Nr. of Employees
medium (51-250)
FinVector
Products
Commercial-scale viral vector drug substance manufacturing
Manufacture of viral vector drug substance at commercial scale to supply finished gene therapy products for clinical and marketed use.
Commercial-scale viral vector drug substance manufacturing
Manufacture of viral vector drug substance at commercial scale to supply finished gene therapy products for clinical and marketed use.
Services
On‑site commercial manufacturing services to produce viral vector drug substances and finished drug products under cGMP for partner biopharma organizations.
Process development, scale-up and technology transfer to enable transition from development-scale processes to commercial manufacturing.
On‑site commercial manufacturing services to produce viral vector drug substances and finished drug products under cGMP for partner biopharma organizations.
Process development, scale-up and technology transfer to enable transition from development-scale processes to commercial manufacturing.
Expertise Areas
- cGMP gene therapy manufacturing
- Viral vector production and purification (adenoviral vectors)
- Process development and scale-up
- Technology transfer for biologics
Key Technologies
- Viral vector manufacturing (adenoviral vectors)
- Fixed‑bed bioreactor platforms
- Upstream cell culture
- Downstream purification
News & Updates
The Finnish Bioindustries awarded FinVector for its significant contributions to medical production development in Finland, especially for the development of the gene therapy Adstiladrin®.
FinVector and Ferring Pharmaceuticals announced the opening of Finport, a state-of-the-art manufacturing facility for viral vector-based gene therapy in Kuopio, Finland.
Priscila Da Silva's story highlights international talent and resilience in the biopharma industry, showcasing her journey from Brazil to Finland and her role at FinVector.
Elisa Kajander’s career at FinVector exemplifies growth, dedication, and leadership in the biotech industry, emphasizing the company’s innovative environment.
Dr. Frederik Paulsen and Professor Seppo Ylä-Herttuala received honorary doctorates from Finnish universities for their significant roles in FinVector's legacy.
Giuseppe Carloni and Jean-Frédéric Paulsen were awarded the prestigious Finnish state orders for their contributions to the construction of FinVector’s manufacturing facility and the approval of gene therapy products.
The Finnish Bioindustries awarded FinVector for its significant contributions to medical production development in Finland, especially for the development of the gene therapy Adstiladrin®.
FinVector and Ferring Pharmaceuticals announced the opening of Finport, a state-of-the-art manufacturing facility for viral vector-based gene therapy in Kuopio, Finland.
Priscila Da Silva's story highlights international talent and resilience in the biopharma industry, showcasing her journey from Brazil to Finland and her role at FinVector.
Elisa Kajander’s career at FinVector exemplifies growth, dedication, and leadership in the biotech industry, emphasizing the company’s innovative environment.
Dr. Frederik Paulsen and Professor Seppo Ylä-Herttuala received honorary doctorates from Finnish universities for their significant roles in FinVector's legacy.
Giuseppe Carloni and Jean-Frédéric Paulsen were awarded the prestigious Finnish state orders for their contributions to the construction of FinVector’s manufacturing facility and the approval of gene therapy products.